Category Archives: News
FDA approved Robotic Brain Surgery from Mazor
![]() |
| Image: Mazor Website. |
FDA approves Mazor robot for brain surgery
“As neurosurgeons focus on both the spine and brain, brain surgeries represent a large market opportunity that is closely aligned with our current focus.”
Mazor Robotics Ltd. has announced that it has obtained US Food and Drug Administration (FDA) approval for its Renaissance surgical guidance system for brain surgery, in addition to spinal procedures. The company will include the brain surgical capability in the same device currently sold for spinal procedures
.
Mazor CEO Ori Hadomi has said in the past that Mazor is a company operating in the spinal procedures field, and that it expected to remain so. The expansion to the brain surgical field is an important addition, but not a core business. Mazor has previously said that the addition of new capabilities to the Renaissance surgical guidance system could allow the company to raise the system’s price, which is currently $750,000 per unit for the spinal surgery version.
Mazor had NIS 9.2 million in sales for the first quarter of 2012. Since April, the company has announced the sale of five additional systems in the US. The company also operates in other countries, where prices for its systems are a bit less than in the US, but the number of sales is about the same. The company obtained marketing approval in South Korea in June.
Mazor is now waiting for EU CE Mark approval for the marketing of the Renaissance system for brain surgery in Europe, where it is currently limited to use for spinal surgical procedures.
Mazor Surgical Technologies has pioneered the development of miniature Semi robotic bone mounted positioning systems SmartAssist platform for a wide range of orthopedic procedures. Mazor is a leading provider of the SpineAssist, a highly accurate, minimally invasive, easy-to-use, miniature surgical assistance system for a wide range of spine procedures. The company was founded by Prof. Moshe Shoham of the Technion Faculty of Mechanical Engineering in order to put his patented robotic innovations into practice.
The Renaissance technology, a surgical guidance system originally designed for use in spine surgeries, is applicable in brain procedures for many applications including biopsies, shunt placements and neurostimulation electrode placement for deep brain stimulation (DBS). Along with the system’s precision, simplicity, and safety profile, the Renaissance System will also provide a frameless treatment solution for brain procedures. Renaissance has already been successfully employed in several clinical brain surgical procedures in Europe. 34 hospitals globally are currently using Renaissance for the different types of spine surgery.
FDA approved Robotic Brain Surgery from Mazor
![]() |
| Image: Mazor Website. |
FDA approves Mazor robot for brain surgery
“As neurosurgeons focus on both the spine and brain, brain surgeries represent a large market opportunity that is closely aligned with our current focus.”
Mazor Robotics Ltd. has announced that it has obtained US Food and Drug Administration (FDA) approval for its Renaissance surgical guidance system for brain surgery, in addition to spinal procedures. The company will include the brain surgical capability in the same device currently sold for spinal procedures
.
Mazor CEO Ori Hadomi has said in the past that Mazor is a company operating in the spinal procedures field, and that it expected to remain so. The expansion to the brain surgical field is an important addition, but not a core business. Mazor has previously said that the addition of new capabilities to the Renaissance surgical guidance system could allow the company to raise the system’s price, which is currently $750,000 per unit for the spinal surgery version.
Mazor had NIS 9.2 million in sales for the first quarter of 2012. Since April, the company has announced the sale of five additional systems in the US. The company also operates in other countries, where prices for its systems are a bit less than in the US, but the number of sales is about the same. The company obtained marketing approval in South Korea in June.
Mazor is now waiting for EU CE Mark approval for the marketing of the Renaissance system for brain surgery in Europe, where it is currently limited to use for spinal surgical procedures.
Mazor Surgical Technologies has pioneered the development of miniature Semi robotic bone mounted positioning systems SmartAssist platform for a wide range of orthopedic procedures. Mazor is a leading provider of the SpineAssist, a highly accurate, minimally invasive, easy-to-use, miniature surgical assistance system for a wide range of spine procedures. The company was founded by Prof. Moshe Shoham of the Technion Faculty of Mechanical Engineering in order to put his patented robotic innovations into practice.
The Renaissance technology, a surgical guidance system originally designed for use in spine surgeries, is applicable in brain procedures for many applications including biopsies, shunt placements and neurostimulation electrode placement for deep brain stimulation (DBS). Along with the system’s precision, simplicity, and safety profile, the Renaissance System will also provide a frameless treatment solution for brain procedures. Renaissance has already been successfully employed in several clinical brain surgical procedures in Europe. 34 hospitals globally are currently using Renaissance for the different types of spine surgery.
Diabetes innovation: 3D vascularized pancreatic islets

Published Scientific Paper.
| PATENT DETAILS3D vascularized pancreatic islets – for islets transplantation |
| Ref. CTT-0895 |
|
The present invention provides a unique 3D pancreatic-like model for co-culture of isolated pancreatic islets with endothelial cells on a PLLA/PLGA biodegradable polymeric scaffold.
Insulin-dependent diabetes mellitus (IDDM) is a chronic inflammatory disease in which there is autoimmune-mediated organ-specific destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in glucose homeostasis abnormalities and metabolic complications that are debilitating and life-threatening. Islet transplantation is a potentially curative treatment since replacement of these cells could prevent mortality, however thus far islet cell transplantation has had poor success due mainly to the fact that the tissue grafts must establish new vasculature from the host to survive. Native islets in the pancreas have a rich microvasculature that provides efficient oxygen and nutrient delivery and ensures rapid dispersal of pancreatic hormones to the circulation, and therefore after implantation, the survival and function of islet grafts depends on reestablishment of new blood vessels. During the time required for revascularization, there is a much-increased susceptibility to loss from ischemic injury, so that rapid and adequate islet revascularization is crucial for the survival and function of transplanted islets. In both experimental and clinical islet transplantations, islets are cultured for several days between isolation and transplantation. The present invention provides an advanced tissue-engineering technique for development of 3D co-culture systems that reconstruct vascularization of pancreatic tissue ex-vivo. In this novel engineered 3D pancreatic model, isolated pancreatic islets can be co-cultured with endothelial cells using PLLA/PLGA biodegradable polymeric scaffolds. The endothelial cells organize into 3D tubes throughout the engineered construct and form vascular network-like structures resembling in-vivo vasculature. This presence of endothelial cells forming 3D vessel-like structures was found critical for islet survival. This model can provide an important tool for therapeutic transplantation of islets, greatly increasing the success of the procedure by increasing islet survival and reducing the number of organ donors needed per transplant and the number of repeated transplants, making this procedure more available, biologically and economically. This model also provides new exciting tools for studying central problems in molecular and cell biology of the pancreas. In the U.S, an estimated 20.8 million people (7% of the population) have diabetes mellitus. In the next five years, around US$2.5 billion will be spent worldwide on diabetes mellitus research. |
Diabetes innovation: 3D vascularized pancreatic islets

Published Scientific Paper.
| PATENT DETAILS3D vascularized pancreatic islets – for islets transplantation |
| Ref. CTT-0895 |
|
The present invention provides a unique 3D pancreatic-like model for co-culture of isolated pancreatic islets with endothelial cells on a PLLA/PLGA biodegradable polymeric scaffold.
Insulin-dependent diabetes mellitus (IDDM) is a chronic inflammatory disease in which there is autoimmune-mediated organ-specific destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in glucose homeostasis abnormalities and metabolic complications that are debilitating and life-threatening. Islet transplantation is a potentially curative treatment since replacement of these cells could prevent mortality, however thus far islet cell transplantation has had poor success due mainly to the fact that the tissue grafts must establish new vasculature from the host to survive. Native islets in the pancreas have a rich microvasculature that provides efficient oxygen and nutrient delivery and ensures rapid dispersal of pancreatic hormones to the circulation, and therefore after implantation, the survival and function of islet grafts depends on reestablishment of new blood vessels. During the time required for revascularization, there is a much-increased susceptibility to loss from ischemic injury, so that rapid and adequate islet revascularization is crucial for the survival and function of transplanted islets. In both experimental and clinical islet transplantations, islets are cultured for several days between isolation and transplantation. The present invention provides an advanced tissue-engineering technique for development of 3D co-culture systems that reconstruct vascularization of pancreatic tissue ex-vivo. In this novel engineered 3D pancreatic model, isolated pancreatic islets can be co-cultured with endothelial cells using PLLA/PLGA biodegradable polymeric scaffolds. The endothelial cells organize into 3D tubes throughout the engineered construct and form vascular network-like structures resembling in-vivo vasculature. This presence of endothelial cells forming 3D vessel-like structures was found critical for islet survival. This model can provide an important tool for therapeutic transplantation of islets, greatly increasing the success of the procedure by increasing islet survival and reducing the number of organ donors needed per transplant and the number of repeated transplants, making this procedure more available, biologically and economically. This model also provides new exciting tools for studying central problems in molecular and cell biology of the pancreas. In the U.S, an estimated 20.8 million people (7% of the population) have diabetes mellitus. In the next five years, around US$2.5 billion will be spent worldwide on diabetes mellitus research. |
Creativity in Organic Synthesis

Professor Ilan Marek, Technion Israel Institute of Technology, Haifa, Israel, has been awarded the Janssen Pharmaceutica Prize for Creativity in Organic Synthesis. The prize is awarded biannually to a chemist under the age of 50 who has made a significant contribution to the field of organic synthesis in the broadest sense.
The Prize consists of a trophy, a citation, and 20,000 Euros. It was presented at the Belgian Organic Synthesis Symposium (BOSS) in Leuven, Belgium, July 15–20, where Professor Marek will deliver a keynote lecture.
Ilan Marek was educated in France and received his Ph.D. from the Universite Pierre et Marie Curie, Paris, in 1988 under the joint supervision of Jean F. Normant, Alexandre Alexakis, and Pierre Mangeney. After a postdoctoral period at Louvain, Belgium, with Leon Ghosez, he worked at the Centre national de la recherche scientifique (CNRS, National Center for Scientific Research). He obtained his Habilitation in 1995 and joined the faculty at the Technion, Haifa, soon after. He was promoted to full professor at the Technion in 2004 and since 2005 he has held the Sir Michael and Lady Sobell Academic Chair.
Marek’s research include the design and development of new and efficient stereo- and enantioselective strategies for the synthesis of important complex molecular structures. In particular, his work focuses on developing carbon-carbon bond forming processes, which efficiently create multiple stereocenters.
Creativity in Organic Synthesis

Professor Ilan Marek, Technion Israel Institute of Technology, Haifa, Israel, has been awarded the Janssen Pharmaceutica Prize for Creativity in Organic Synthesis. The prize is awarded biannually to a chemist under the age of 50 who has made a significant contribution to the field of organic synthesis in the broadest sense.
The Prize consists of a trophy, a citation, and 20,000 Euros. It was presented at the Belgian Organic Synthesis Symposium (BOSS) in Leuven, Belgium, July 15–20, where Professor Marek will deliver a keynote lecture.
Ilan Marek was educated in France and received his Ph.D. from the Universite Pierre et Marie Curie, Paris, in 1988 under the joint supervision of Jean F. Normant, Alexandre Alexakis, and Pierre Mangeney. After a postdoctoral period at Louvain, Belgium, with Leon Ghosez, he worked at the Centre national de la recherche scientifique (CNRS, National Center for Scientific Research). He obtained his Habilitation in 1995 and joined the faculty at the Technion, Haifa, soon after. He was promoted to full professor at the Technion in 2004 and since 2005 he has held the Sir Michael and Lady Sobell Academic Chair.
Marek’s research include the design and development of new and efficient stereo- and enantioselective strategies for the synthesis of important complex molecular structures. In particular, his work focuses on developing carbon-carbon bond forming processes, which efficiently create multiple stereocenters.
Diabetes Research and Vascular Networks
Diabetes Research and Vascular Networks
The “God Particle” & Technion
![]() |
| A view of the center of the ATLAS |
Technion researchers are playing important roles at the LHC project in CERN – the world’s most powerful particle accelerator. Recently, news reports say the greatest scientific experiment in history has had amazing results and that the Higgs Boson – alias the “God particle” – has been discovered.
During the sixties and seventies, a model was developed that explains phenomena observed in the world of particles that comprise the entire universe. The model, which is called the “Standard Model”, explains brilliantly and accurately all experimental results and observations. But this model has originally had a problem: it could not be used to explain particles that have a mass. It is simply that mathematically, the equations did not hold if the mass of these particles was added to them. In the mid-sixties, several physicists, among them Peter Higgs, suggested what is currently known as the “Higgs mechanism”, through which mass can be added to the Standard Model. But adding this mechanism meant that a new particle had to exist – the Higgs Boson. We have been searching for it ever since. Last night, the world was told of its discovery.
This is, without a doubt, a technological achievement, but the real achievement is not in the technological realm, but rather in the news that the model we have been following is likely the correct one. We have, in fact, completed our first puzzle. We can now safely proceed in search of the next puzzle, namely the “new physics” or “physics beyond the Standard Model”, where we investigate phenomena that are not described by the Standard Model. Each such discovery, if made, will completely change our perception of the universe around us.
The Technion group has made a major contribution to the discovery, in that the construction and examination of the muon detectors, which are a critical part of the experiment’s ability to measure the events, were done in Israel. The muon detection software was developed by Prof. Tarem, and Prof. Rozen is responsible for the tremendous grid computing system. Students guided by Prof. Tarem developed the detector control system, and several students and researchers are now working under her guidance on one of the Higgs decay channels, as presented in the press conference last night.
About three years ago, only a moment before the huge tunnel in which the accelerator was built was sealed, Avi Blizovsky visited the place and we now bring his impressions once again.
We visited “ATLAS” – one of the main detectors in the LHC project in CERN. In a modest office in building number 40 – one of the main buildings on the CERN campus – seats Prof. Shlomit Tarem, of the High Energy Group in the Technion’s Department of Physics. Prof. Tarem is participating in the project together with her colleague in the group, Prof. Yoram Rozen, and their graduate students. The office houses also post-doctoral fellow Sofia Vallecorsa (originally of Rome) and doctoral student Sagi Ben-Ami. Among the Israeli group members are also researchers from the Weizmann Institute and Tel Aviv University. With them works Arwa Bannoura, a student from Birzeit who lives in Bethlehem, and who is currently in CERN for the summer semester.
The Israeli group is headed by Giora Mikenberg of the Weizmann Institute, who has held in the past formal positions in CERN. According to Mikenberg, the credit for Israel joining the project is due, first and foremost, to the late Prof. Paul Singer of the Technion’s Department of Physics, who served as Chairman of the Israel Science Foundation.
During its construction, Israeli engineers collaborated with engineers of the Pakistan Atomic Energy Commission, and Israeli equipment allows fast and accurate optical communications between the facilities and the enormous server cluster. Many Israeli companies participated in building “ATLAS”, the huge facility that comprises 2,700 detectors on eight “wheels” 20 meters in diameter. Once the tunnel was sealed in August it could no longer be entered, which emphasizes the importance of the examinations conducted toward this move, to avoid technicians having to enter the tunnel in order to make repairs once the experiment begins.
The different elements of the CERN project were indeed examined prior to the start of the experiment, but the operation of the project as a whole could not be tested at the time. As was announced, the project was shut down for two months shortly after it began, because of a helium leak, but Prof. Tarem cautions against any concern. “This experiment will last for at least a decade, so two months are not too significant a period. Besides, malfunctions cannot be avoided in such a big, complicated experiment.”
Today, Profs. Tarem and Rozen and thousands of their colleagues worldwide can smile with pride and satisfaction. They were part of the discovery of the “God particle”.
![]() |
|
A graphic diagram of the particle accelerator in Geneva
|
![]() |
| From right to left: Eli Hadash, Shikma Bressler, Silvia Behar, David Cohen, Yoram Gernitzky, Alon Hershenhorn and Yaniv Katan. In the second row: Sofia Vallecorsa, Dikla Oren, and Enrique Kachomovitz. Prof. Rozen (horizontal). |
PRESIDENT’S REPORT 2015








